PMID- 31544361
OWN - NLM
STAT- MEDLINE
DCOM- 20200521
LR  - 20201101
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Print)
IS  - 1934-662X (Linking)
VI  - 127
IP  - 11
DP  - 2019 Nov
TI  - HER2 assessment by bright-field dual in situ hybridization in cell blocks of 
      recurrent and metastatic breast carcinoma.
PG  - 684-690
LID - 10.1002/cncy.22184 [doi]
AB  - BACKGROUND: Breast cancer recurrences or metastases often are diagnosed using 
      cytology material. Cell blocks (CBs) with adequate cellularity are crucial for 
      the determination of accurate hormonal and human epidermal growth factor receptor 
      2 (HER2) status and to guide treatment. In the current study, the authors 
      evaluated the concordance of HER2 status between bright-field dual in situ 
      hybridization (DISH), fluorescence in situ hybridization (FISH), and HER2 
      immunohistochemistry (IHC) performed on formalin-fixed CBs of recurrent and 
      metastatic breast cancers. METHODS: The authors searched for patients who had 
      breast carcinoma recurrences or metastases diagnosed between 2010 and 2018 by 
      fine-needle aspiration or by the drainage of body cavity fluids with HER2 IHC 
      and/or FISH performed on formalin-fixed CBs. Cases with adequate tumor 
      cellularity (>50 cells) were selected. HER2 DISH was performed on all CBs. HER2 
      status of the primary breast carcinoma was recorded. RESULTS: Formalin-fixed CBs 
      were identified from 30 patients with breast cancer recurrences and metastases in 
      axillary lymph nodes (LNs) (5 patients), mediastinal LNs (8 patients), internal 
      mammary LNs (1 patient), supraclavicular LNs (2 patients), portocaval LNs (1 
      patient), chest wall (3 patients), pleural fluid (3 patients), bone (4 patients), 
      liver (2 patients), and lung (1 patient). All cases had HER2 IHC performed at the 
      study institution and were scored by breast pathologists according to the 
      American Society of Clinical Oncology/College of American Pathologists 
      guidelines. The HER2 DISH results demonstrated 100% concordance (30 of 30 cases) 
      with the concurrent IHC and/or FISH. CONCLUSIONS: All methods of HER2 evaluation 
      were found to accurately identify the amplification status. DISH can be used in 
      tandem with IHC as a reflex assay instead of FISH and is an efficient and 
      reliable method with which to determine HER2 amplification in formalin-fixed CBs.
CI  - (c) 2019 American Cancer Society.
FAU - Edelweiss, Marcia
AU  - Edelweiss M
AUID- ORCID: 0000-0001-6288-5244
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Sebastiao, Ana Paula Martins
AU  - Sebastiao APM
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Oen, Handy
AU  - Oen H
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Kracun, Mihaela
AU  - Kracun M
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Serrette, Rene
AU  - Serrette R
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
FAU - Ross, Dara S
AU  - Ross DS
AD  - Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New 
      York.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
GR  - P30CA008748/National Cancer Institute of the National Institutes of 
      Health/International
GR  - P30CA008748/Cancer Center Support Grant of the National Institutes of 
      Health/National Cancer Institute/International
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20190922
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*chemistry/pathology
MH  - Carcinoma, Ductal, Breast/*chemistry/pathology/secondary
MH  - Carcinoma, Lobular/*chemistry/pathology/secondary
MH  - Female
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization/*methods
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*chemistry
MH  - Receptor, ErbB-2/*analysis
PMC - PMC6848761
MID - NIHMS1047965
OTO - NOTNLM
OT  - breast cancer
OT  - cell block cytology
OT  - chromogenic in situ hybridization
OT  - dual in situ hybridization (DISH)
OT  - human epidermal growth factor receptor 2 (HER2)
COIS- Disclosure of conflict of interest: The authors declare no conflict of interest
EDAT- 2019/09/24 06:00
MHDA- 2020/05/22 06:00
PMCR- 2020/11/01
CRDT- 2019/09/24 06:00
PHST- 2019/06/14 00:00 [received]
PHST- 2019/08/02 00:00 [revised]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/09/24 06:00 [pubmed]
PHST- 2020/05/22 06:00 [medline]
PHST- 2019/09/24 06:00 [entrez]
PHST- 2020/11/01 00:00 [pmc-release]
AID - 10.1002/cncy.22184 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2019 Nov;127(11):684-690. doi: 10.1002/cncy.22184. Epub 2019 
      Sep 22.